Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials.
Krishnan A, Callanan DG, Sendra VG, Lad A, Christian S, Earla R, Khanehzar A, Tolentino AJ, Vailoces VAS, Greene MK, Scott CJ, Kunimoto DY, Hassan TS, Genead MA, Tolentino MJ. Krishnan A, et al. Among authors: kunimoto dy. Pharmaceuticals (Basel). 2024 Apr 9;17(4):481. doi: 10.3390/ph17040481. Pharmaceuticals (Basel). 2024. PMID: 38675441 Free PMC article.
PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration.
Peterson SL, Krishnan A, Patel D, Khanehzar A, Lad A, Shaughnessy J, Ram S, Callanan D, Kunimoto D, Genead MA, Tolentino MJ. Peterson SL, et al. Pharmaceuticals (Basel). 2024 Apr 17;17(4):517. doi: 10.3390/ph17040517. Pharmaceuticals (Basel). 2024. PMID: 38675477 Free PMC article.
Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial.
Boyer DS, Gonzalez VH, Kunimoto DY, Maturi RK, Roe RH, Singer MA, Xavier S, Kornfield JA, Kuppermann BD, Quiroz-Mercado H, Aubel J, Karageozian HL, Park JY, Karageozian VH, Karageozian L, Sarayba MA, Kaiser PK. Boyer DS, et al. Among authors: kunimoto dy. Ophthalmic Surg Lasers Imaging Retina. 2021 Jun;52(6):327-335. doi: 10.3928/23258160-20210528-05. Epub 2021 Jun 1. Ophthalmic Surg Lasers Imaging Retina. 2021. PMID: 34185587 Free article. Clinical Trial.
Program-wide review and follow-up of erythema Induratum of Bazin and tuberculosis-associated ocular inflammation management in a TB low-incidence setting: need for improved treatment candidate selection, therapy standardization, and care collaboration.
Connors WJ, Fisher DA, Kunimoto DY, Jarand JM. Connors WJ, et al. Among authors: kunimoto dy. BMC Infect Dis. 2019 Jan 29;19(1):97. doi: 10.1186/s12879-019-3737-5. BMC Infect Dis. 2019. PMID: 30696400 Free PMC article.
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group. Scott IU, et al. Among authors: kunimoto dy. JAMA. 2017 May 23;317(20):2072-2087. doi: 10.1001/jama.2017.4568. JAMA. 2017. PMID: 28492910 Free PMC article. Clinical Trial.
Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial.
Kuppermann BD, Goldstein M, Maturi RK, Pollack A, Singer M, Tufail A, Weinberger D, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex® ERIE Study Group. Kuppermann BD, et al. Ophthalmologica. 2015;234(1):40-54. doi: 10.1159/000381865. Epub 2015 Jun 18. Ophthalmologica. 2015. PMID: 26088793 Free article. Clinical Trial.
62 results